LUCD News and Press, Lucid Diagnostics Inc. From 05/09/24

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall PR Newswire EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck ® unaffected by recall and remains the gold standa...

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors PR Newswire Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President ...

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 PR Newswire Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or...

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing PR Newswire EsoGuard demonstrated unprecedented early precancer de...

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month PR Newswire NEW YORK , April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commer...

2024-04-19 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Let’s just get something straight off the bat – penny stocks to rebound are risky. They’re incredibly treacherous in terms of both short-term downside and longer-term d...

2024-04-08 09:00:06 ET Mark Massaro from BTIG issued a price target of $2.50 for LUCD on 2024-04-08 07:51:00. The adjusted price target was set to $2.50. At the time of the announcement, LUCD was trading at $0.9277. The overall price target consensus is at $3.30 with hig...

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire NEW YORK , April 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention...

PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results PR Newswire Lucid's quarterly revenue increased 33 percent sequentially Launched wholly-owned incubator, PMX, to complete development and commercialization of existing portfolio tec...

2024-03-26 16:27:08 ET Lucid Diagnostics Inc. (LUCD) Q4 2023 Earnings Conference Call March 26, 2024, 08:30 AM ET Company Participants Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Kyle Mikson - Canaccord Joseph Con...